Method of treatment of age-related macular degeneration (amd)
Abstract
The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.
Claims
exact text as granted — not AI-modified1 . A method for treating a subject with age-related macular degeneration (AMD) said method comprising administering to said subject an amount of PB-1033:
or a pharmaceutically acceptable salt, derivative or functional equivalent thereof effective to reduce metal in retinal drusen to a level which ameliorates symptoms of AMD.
2 . The method of claim 1 wherein the subject is a mammal.
3 . The method of claim 2 wherein the mammal is a human.
4 . The method of claim 1 or 2 or 3 wherein the metal is selected from the list consisting of zinc and copper.
5 . The method of claim 1 or 2 or 3 or 4 wherein derivative or functional equivalent of PB-1033 is selected from the list in Table 8 or pharmaceutically acceptable salts, derivatives or functional equivalents thereof.
6 . The method of claim 5 wherein the derivative or functional equivalent of PB-1033 is selected from the list consisting of PB-1076, PB-1085, PB-1120, PB-1127, PB-1135, PB-1149, PB-1151, PB-1160 and PB-1168 or pharmaceutically acceptable salts, derivatives or functional equivalents thereof.
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . A method for reducing levels of a metal from retinal drusen in a subject to thereby ameliorate symptoms of age-related macular degeneration (AMD) said method comprising administering to said subject an effective amount of PB-1033:
or a pharmaceutically acceptable salt, derivative or equivalent thereof.
15 . The method of claim 14 wherein the subject is a mammal.
16 . The method of claim 15 wherein the mammal is a human.
17 . The method of claim 14 or 15 or 16 wherein the metal is selected from the list consisting of zinc and copper.
18 . The method of claim 14 or 15 or 16 or 17 wherein derivative or functional equivalent of PB-1033 is selected from the list in Table 8 or pharmaceutically acceptable salts, derivatives or functional equivalents thereof.
19 . The method of claim 14 wherein the derivative or equivalent of PB-1033 is selected from the list consisting of PB-1076, PB-1085, PB-1120, PB-1127, PB-1135, PB-1149, PB-1151, PB-1160 and PB-1168 or pharmaceutically acceptable salts, derivatives or functional equivalents thereof.
20 . A compound selected from the following:
21 . The compound of claim 20 which is selected from PB 1267, PB 1268, PB 1269 and PB 1271.
22 . The compound of claim 21 which is PB 1268.
23 . The compound of claim 20 which is PB 1135 or PB 1149.Join the waitlist — get patent alerts
Track US2010144693A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.